NFKB1 and cancer: Therefore, although targeting upstream NF-κB signalling components has yielded tangible clinical results in the treatment of certain cancers and represents an attractive therapeutic strategy from the standpoint of achieving a degree of tissue- and context-specificity, this approach has so far been limited by the onset of dose-limiting adverse effects, inherent cancer recalcitrance and/or an early onset of secondary drug resistance [109,113,130].